New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
25/02/2021 - 14:30 ); );
MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing
Initial findings from the CLOCK-MS vaccine sub-study show protective influenza antibody levels at four weeks post-vaccination in MS patients taking MAVENCLAD
In both studies, protective antibody levels were maintained or increased independent of lymphocyte counts
DARMSTADT, Germany, Feb. 25, 2021 /PRNewswire/
Not intended for UK and U.S. based media
Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosis (RMS) at the Americas Commit
25 febbraio 2021 14:05
Fonte: Adnkronos
#chimica-e-farmacia
MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing
Initial findings from the CLOCK-MS vaccine sub-study show protective influenza antibody levels at four weeks post-vaccination in MS patients taking MAVENCLAD
In both studies, protective antibody levels were maintained or increased independent of lymphocyte counts
DARMSTADT, Germany, Feb. 25, 2021 /PRNewswire/
Not intended for UK and U.S. based media
Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosis (RMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, being held virtually 25-27 Feb
New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021
News provided by
Share this article
Share this article
TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27. Nine Janssen-sponsored data abstracts on MS research will be presented, including real-world evidence highlighting the impact of fatigue in U.S. adults with relapsing MS (RMS); a study assessing the impact of MS fatigue on work productivity and activity impairment; and cross-sectional analyses of both the economic and humanistic burden associated with fatigue in relapsing-remitting MS.
4.5 (28)
The 2020 Barancik Prize for Innovation in MS Research has been awarded to neuroscientist Dwight E. Bergles, PhD, a Johns Hopkins University professor, for his work in understanding the function of brain cells in multiple sclerosis (MS).
This international prize awards $100,000 to the recipient.
Administered by the National MS Society, the prize seeks to “recognize and encourage exceptional innovation and originality in scientific research” into the causes and potential treatments for multiple sclerosis.
Myelin, the fat-rich substance that wraps around nerve fibers (axons), works to insulate and increase the velocity of signals relayed by nerve cells. Myelin loss is the underlying cause of diseases like MS.